70G Stock Overview
A biotechnology company, engages in the research, development, and commercialization bacteriophage therapies to treat bacterial infections affecting human health, animal health, and food security in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Cytophage Technologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.21 |
| 52 Week High | CA$0.21 |
| 52 Week Low | CA$0.14 |
| Beta | 0.10 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 26.61% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| 70G | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 42.3% | -0.7% | -0.02% |
| 1Y | n/a | -17.2% | 8.2% |
Return vs Industry: Insufficient data to determine how 70G performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 70G performed against the German Market.
Price Volatility
| 70G volatility | |
|---|---|
| 70G Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 70G's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 70G's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Steven Theriault | cytophage.com |
Cytophage Technologies Ltd., a biotechnology company, engages in the research, development, and commercialization bacteriophage therapies to treat bacterial infections affecting human health, animal health, and food security in Canada. It develops poultry health products under the AviPhage name; food safety products under the PhageFend name; bovine mastitis products under the BoviPhage name; and water-soluble solution for livestock producers under the FarmPhage name. The company is headquartered in Winnipeg, Canada.
Cytophage Technologies Ltd. Fundamentals Summary
| 70G fundamental statistics | |
|---|---|
| Market cap | €12.04m |
| Earnings (TTM) | -€5.39m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.2x
P/E RatioIs 70G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 70G income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$7.85m |
| Earnings | -CA$7.85m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 70G perform over the long term?
See historical performance and comparison